Clinical Trials

Are New Innovations Revolutionizing Urticaria Treatment Options?
Research & Development Are New Innovations Revolutionizing Urticaria Treatment Options?

Urticaria, commonly known as hives, is a prevalent skin condition affecting up to 20% of the global population at some point in their lives, causing a significant impact on individuals' quality of life. It is characterized by the rapid appearance of raised, itchy welts or wheals on the skin

Is Sanofi’s Shift to Pure Biopharma the Future of Healthcare Innovation?
Management & Regulatory Is Sanofi’s Shift to Pure Biopharma the Future of Healthcare Innovation?

In October 2023, Sanofi, a leading global pharmaceutical company, announced a major shift in its business strategy. This shift involved the separation of its consumer health division, a move set to be completed in 2024. Historically, Sanofi's consumer health division, which includes popular

How Are Financial Reports and AI Impacting the Biopharma Industry?
Research & Development How Are Financial Reports and AI Impacting the Biopharma Industry?

The biopharma industry is currently navigating a complex landscape marked by significant financial developments and technological advancements. Recent financial reports from key players like Moderna and Gilead Sciences, coupled with the growing use of artificial intelligence (AI) in clinical

What Is Driving Sana Biotechnology's Major Strategic Shift?
Research & Development What Is Driving Sana Biotechnology's Major Strategic Shift?

In a significant move just three years post its highly successful IPO, Sana Biotechnology has announced a strategic restructuring that will likely reshape the company's future and impact. This overhaul will include layoffs and a refocused research directive, marking a notable shift in

Arcellx and Gilead's New Therapy Shows Promise for Multiple Myeloma
Research & Development Arcellx and Gilead's New Therapy Shows Promise for Multiple Myeloma

The ongoing search for better and safer treatments for multiple myeloma, a type of blood cancer, has taken a significant step forward with the development of a new cell therapy by Arcellx and Gilead Sciences. The pioneering approach demonstrated a substantial reduction or total eradication of

Naobios and Sumagen Achieve Milestone in HIV-1 Vaccine Development
Research & Development Naobios and Sumagen Achieve Milestone in HIV-1 Vaccine Development

Naobios and Sumagen Canada Inc., a subsidiary of CreoSG Co., Ltd, have achieved a critical milestone in the development of Sumagen’s HIV-1 vaccine candidate, SAV001. This genetically modified, whole-killed HIV vaccine has shown both tolerance and safety in phase I trials, marking a significant step

Loading

Subscribe to our weekly news digest.

Join now and become a part of our fast-growing community.

Invalid Email Address
Thanks for Subscribing!
We'll be sending you our best soon!
Something went wrong, please try again later